A supplemental application for Keytruda (pembrolizumab) received FDA approval for efficacy on August 10, 2021. This approval was granted to sponsor Merck Sharp Dohme, indicating that new data supported an expansion of the drug's approved uses.
What this means
The supplemental FDA approval for Keytruda (pembrolizumab) on August 10, 2021, is a significant regulatory action that confirms the drug's demonstrated efficacy for an expanded use. Supplemental applications are filed by drug sponsors, in this case Merck Sharp Dohme, to request approval for changes to an already approved drug product. These changes can include new indications, new patient populations, new dosing regimens, or new manufacturing processes. An approval for "efficacy" specifically means that the FDA has reviewed new clinical data and determined that pembrolizumab is effective for the proposed new use. For clinicians, this expansion provides additional treatment options, allowing them to consider pembrolizumab for a broader range of patients or conditions where its benefit has now been officially recognized. Researchers will note this as an example of how ongoing clinical development can extend the utility of established therapies. Patient advocates can also view this as a positive development, potentially increasing access to an effective treatment for more individuals.
Source
The information regarding this supplemental FDA approval was obtained from the official FDA website, specifically the Drugs@FDA database. The approval for BLA 125514 S-102 was recorded on August 10, 2021, on accessdata.fda.gov. This public record provides transparent access to regulatory actions for approved drug products.